Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with.
Ocular Therapeutixtm Announces Positive Phase 2 PAXTRAVATM Glaucoma Data At The American Society Of Cataract And Refractive Surgery 2024 Annual Meetin menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
11.03.2024 - Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA in Glaucoma Expected in Q2 2024 Cash .
Ocular Therapeutix™ Reports Fourth Quarter And Full Year 2023 Results menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Ocular Therapeutix (NASDAQ: OCUL) has recently received a number of price target changes and ratings updates: 3/10/2024 – Ocular Therapeutix was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating. 3/2/2024 – Ocular Therapeutix was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 2/26/2024 – Ocular […]